RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS

Thirty‐five dogs with naturally occurring PDH initially treated with low doses of trilostane (range 0.27‐1.14mg/kg/12h) were included. TD was adjusted based on clinical signs and the results of an ACTH stimulation test (3‐4 hours post‐trilostane). Rechecks were performed at day 7 and 30 and thereafter every 3 months. Several parameters (age, sex, clinical and laboratory findings, concurrent diseases and clinical signs at diagnosis) were evaluated in relation with the evolution of TD. Dogs were divided into two groups according to the initial TD: Group‐A (0.27‐0.6mg/kg/12h; n=18) and Group‐B (0.61‐1.14mg/kg/12h; n=17). Sex, age, clinical and laboratory findings and concurrent diseases were not significantly different between the 2 groups (p>0.05).